Monogram Orthopedics Develops Futuristic Joint Replacement Robots - KingsCrowd

Analyst Report: Upgrade for access Monogram Orthopedics Develops Futuristic Joint Replacement Robots

Monogram Orthopedics is combining 3D printing and robotics for customized joint replacements. It could massively disrupt orthopedic surgery.

Company: Monogram Orthopedics on DealMaker Securities 2022
Security Type: Equity - Preferred
Valuation: $155,000,000
Min Investment: $500
Platform: Dealmaker Securities
Deadline: Nov 21, 2022
Teddy Lyons - September 30th

The Future is Here

If someone asked you what the two most capital-intensive industries are, what would you say?  

To me, the answer is crystal clear: medical technology and robotics.  

For medical technology companies, getting FDA approval is a very expensive (but completely necessary) undertaking, particularly if clinical trials are necessary. For robotics companies, product development and prototyping require major amounts of capital.  

Monogram Orthopedics, a Texas-based startup, has managed to cost-effectively merge these two industries. 

The company is developing a robot that is able to perform knee and hip replacements without any user-initiated movements. Monogram is hoping (in the next few years) to deliver the following three-step patient experience:

Step 1: A computerized tomography (CT) scan of a patient’s knee/hip is taken to develop a virtual “map” of the affected area.

Step 2: An artificial intelligence-powered 3D printer creates a patient-specific press-fit implant (cementless implants believed to show higher stability than cemented implants, which are used in 92% of knee-transplants now) that matches the exact anatomy of each individual patient.

Step 3: Using the data from the CT scan, a robotic arm makes a precise cut in the knee/hip and inserts the custom implant with a high degree of accuracy. 

Higher precision and faster surgeries. That’s the name of the game with Monogram.

At first glance, this may seem too futuristic (and borderline impossible).  

I’m here to tell you that Monogram has nearly done it. The company is conducting live surgical demonstrations of its robot for the orthopedic community and is gearing up for FDA submission.  

Once the company’s robot is approved by the FDA, Monogram will launch its first-generation knee offering with generic implants. Once this has been successfully rolled out to hospitals, the company will release its second generation of implants: 3D-printed implants that closely match a patient’s anatomy and stand to disrupt this space in a major way.  

Let’s break our analysis of Monogram into three parts:

  • Why is this technology better than legacy competitors’?
  • Does the team have the experience to commercialize this technology?
  • What are the risks?
Pay Annually
and save 17%

This article requires: Edge Pro

Full site access including KingsCrowd's qualitative analyst reports.

49.95 /month
41.58 /annually

What's included

  • Everything in Edge, plus
  • Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
  • Search and filter based on Analyst Reports
  • In-depth risk ratings for every raise

Get access to the first and only premium analytics and rating platform that enables informed startup investments.

Join the KingsCrowd insiders!

Sign up for our 3 minute newsletter with fresh takes on the investments you should know.

We care about the protection of your data. Read our Privacy Policy.